Results 231 to 240 of about 1,192,795 (361)

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Clinical benefits of <i>Bifidobacterium infantis</i> YLGB-1496 in modulating gut microbiota and immunity in young children. [PDF]

Front Nutr
Uma Mageswary M, Li P, Richmond RV, Azianey Y, Abd Hamid IJ, Taib F, Liong MT, Ali A, Tan JS, Zhang Y.   +9 more
europepmc   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Euglena gracilis Suppresses Cold Symptoms in Healthy Individuals: A Double‐Blind, Randomized, Placebo‐Controlled Trial

Ayaka Nakashima, Kengo Suzuki, Masafumi Nagata, Tsuyoshi Takara   +3 more
openalex   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

CL22209, a standardized <i>Asparagus racemosus</i> root extract, demonstrates improved ovarian morphology, menstrual regularity, and metabolic parameters in women with polycystic ovary syndrome in a randomized, controlled trial. [PDF]

Food Nutr Res
Kondamudi S, Sadu S, Deva S, Yalamanchi A, Yalamanchi A.   +4 more
europepmc   +1 more source

Placebos, Active Placebos, and Clinical Trials [PDF]

Clinical Therapeutics, 2017
openaire   +2 more sources

Effect of pre-endoscopy intake of simethicone solution on endoscopic mucosal visibility: A single blinded, placebo control, randomized trial

, 2019
Bader Faiyaz Zuberi, Majid Ahmed Shaikh, Faiza Sadaqat Ali, Tazeen Rasheed, Zunaira Nawaz   +4 more
openalex   +2 more sources

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source